In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Linnea Burman, Vice President & General Manager, Enabling Technologies: Cranial & Spinal Technologies at Medtronic. She speaks about the company’s interest in Mazor Robotics and why they made the acquisition. Burman also speaks about the evolving robotic surgical landscape as well as what’s ahead for Medtronic within the space. Specifically, the following questions are addressed.  
  

• Let’s start with the significant news Medtronic made a couple years ago when they purchased Mazor. What’s the latest with that robotic surgical technology?
• What was it about Mazor that made it such an attractive target to Medtronic?
• While the Mazor is indicated for orthopedic surgery, there’s been talk of Medtronic’s initiatives for a soft tissue robotic surgical solution. Can you speak to that at all?
• The da Vinci aside, the soft tissue space for robotic surgery seems to be a longer development cycle compared to orthopedics. Do you have any insight why this seems to be the case?
• While current robotic surgical systems are very exciting, we’re only at the early stages of development. Without giving away all the secrets, where do you see this technology headed? 

 Listen to this episode and see what you think of Medtronic’s current and future robotic surgical solution initiatives. If you’d like to share thoughts, ask questions, or suggest a future participant for Medtech Matters, please reach out to me at [email protected].
 
Listen to the podcast streaming via the player or get the podcast on the Medtech Matters channel via your preferred vendor of podcasts, such as Apple Podcasts (iTunes) or Spotify.

Send us a text

For more medtech news and information, visit https://www.mpomag.com.